OBJECTIVE
To calculate cost difference between two approaches for immunosuppressive therapy after renal transplantation: everolimus plus reduced-exposure cyclosporine (Ev+Cyc_red) and mycophenolic acid plus standard-exposure cyclosporine (MA+Cyc_st) for Russian healthcare system
METHODS
The calculation of the cost difference between alternative immunosupressive strategies after renal transplantation • The probability model was constructed to estimate costs of immunosuppressive therapy after renal transplantation.
•
The model compares two scenarios when patient receives immunosuppressive therapy after renal transplantation: 1) Ev+Cyc_red, 2) MA+Cyc_st.
The 2 year time horizon was considered.
The model was based on the results of randomized controlled trial (Cibrik D. [3] ), and the results of the expert survey (Tab. 1).
The model takes into account the following types of direct medical costs: ▪ urinary tract infection.
The model does not take into account the cost of therapy and medical assistance provided under comparable strategies in the same amount.
• Direct medical costs were calculated from the Russian healthcare system point of view.
Costs were estimated on the basis of data on fixed manufacturers' prices register for vital and essential drugs (except everolimus when non-registered manufacturer's price was taken) and reimbursement rates for services in the compulsory medical insurance system.
Budget impact analysis from federal drug provision program perspective •
The Markov model was constructed to calculate the number of patients after renal transplantation, that will receive the Ev+Cyc due to the inclusion of everolimus into the drug provision program where X t,i -the number of patientsof the year t, i -the time since the inclusion of everolimus in the drug provision program.
RESULTS
Ev+Cyc_red leads to cost reduction by €2.3 thousands (17%) per patient in a two-year period when compared to MA+Cyc_st. The reduction mainly results from less costs for immunosuppressive drugs in Ev+Cyc_red approach compared to MA+Cyc_ st (Fig.1) . Also costs for cytomegalovirus infection prevention and treatment are smaller in Ev+Cyc_red strategy. Based on the results of the Markov modeling number of patients in these groups (Tab. 2), it is estimated that everolimus inclusion into federal drug provision program will lead to reduction in federal budget spending starting from the first year; the total five-year budget savings are €4.7 million 1 (Tab. 3). 
CONCLUSIONS
Ev+Cyc_red is a cost-saving option for immunosuppressive therapy after renal transplantation in Russia when compared with MA+Cyc_st.
